공고 • Mar 26
PsyBio Therapeutics Listing Transfer from Tier 2 to NEX In accordance with TSX Venture Policy 2.5, PsyBio Therapeutics Corp. has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on March 27, 2024, the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Toronto to NEX. As of March 27, 2024, the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the Company will change from PSYB to PSYB.H. There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital. The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market. Further to the TSX Venture bulletin dated December 6, 2023, trading in the shares of the Company will remain suspended. Members are prohibited from trading in the securities of the Company during the period of the suspension or until further notice. 공고 • Jan 11
PsyBio Therapeutics Corp. Appoints Ian Wisenberg to the Board of Directors PsyBio Therapeutics Corp. announced the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an independent member of the Company's audit committee. Mr. Wisenberg's career spans over three decades in biotechnology international business with an emphasis in finance, capital formation, corporate and business development. Ian has been an integral leader charting innovation and growth across several Bridgewest Group biotech companies. As CEO and board director of BioCina Pty Ltd., he leads a highly accomplished team, recognized for its strong history as a multi-product biologics development and manufacturing. Prior to taking the helm at BioCina, Ian was founder and Chief Business Officer of BioArdis, Chief Financial Officer at BioDuro and previous to these roles ran a very successful global life sciences consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad. Ian is from Cape Town, South Africa, and attended the University of Cape Town. 공고 • Dec 10
PsyBio Therapeutics Corp. Files Three New Provisional Patent Applications, Including Intellectual Property Protection for Biosynthetic Production of 5-MeO-DMT PsyBio Therapeutics Corp. announced the filing of three additional U.S. Provisional Patent Applications covering its new discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen. The National Park Service posted a request recently warning visitors not to lick the Sonoran Desert Toad (Incilius alvarius), as reported online by the Smithsonian Magazine. The report describes that widespread use of 5-MeO-DMT could have disastrous effects for Sonoran Desert Toads and, as a result, that conservationists are urging people to use synthetic alternatives. The three provisional patent applications comprise advancements concerning production methodology, host strains and processes of production that further support and allow PsyBio's novel production platform methodology to be patent protected including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT, which is environmentally safer than synthetic production methodology. 공고 • Dec 07
PsyBio Therapeutics Corp. Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio PsyBio Therapeutics Corp. announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by PsyBio to ten. The four U.S. PCT Patent Applications were filed based upon five provisional patents comprising advancements concerning production methodology, host strains and processes of production that are expected to support and allow PsyBio's novel production methodology to be patent protected. These filings demonstrate the company's ongoing commitment to value creation while promoting scientific and methodologic advancements in the field. 공고 • Dec 02
PsyBio Therapeutics Corp. announced that it expects to receive CAD 1 million in funding PsyBio Therapeutics Corp. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on December 1, 2022. Each unit will consist of one subordinate voting share and one share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at an exercise price of CAD 0.10 per warrant share for a period of two years from the first closing date, or 30 days after the date on which the company gives notice of acceleration, which notice may be provided no earlier than four months and twenty-one days from the date of issue if the closing price of the common shares on a stock exchange in Canada is higher than CAD 0.20 per common share for more than 10 non-consecutive trading days. Closing of the offering may be completed in multiple tranches and is subject to certain closing conditions including, but not limited to, conditional approval from the TSX Venture Exchange and receipt of any other required regulatory approvals. The securities being offered under the offering will be issued pursuant to applicable exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the date of issue. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Bob Oliver was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
